AKEBIA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: John P. Butler

AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: John P. Butler”): 130,424,556 for, 20,706,403 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 33,758,405 for, 104,299 withheld, 9,563 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Myles Wolf

AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Myles Wolf, M.D., M.M.Sc.”): 119,938,011 for, 31,192,948 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 29,503,975 for, 4,239,146 withheld, 129,146 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Approve an amendment to the Akebia Therapeutics, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to the plan;

AKEBIA THERAPEUTICS INC.’s own tally for this item (“2. Proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to ”): 102,750,481 for, 48,208,800 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to the plan was approved as follows:”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 33,473,759 for, 399,051 against.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Description as filed by funds: Hold an advisory vote on the compensation of Akebia's named executive officers;

AKEBIA THERAPEUTICS INC.’s own tally for this item (“3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers”): 110,676,718 for, 39,006,990 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers was approved as follows:”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 33,758,517 for, 113,750 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 104 managers: 44,597,588 for, 614,469 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and

AKEBIA THERAPEUTICS INC.’s own tally for this item (“4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 178,590,132 for, 8,896,080 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 33,868,893 for, 3,374 against.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.